BSE · 524723
Arvaya Healthcare Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Shareholding
As of 2026-06-30
- Promoter30.62%
- Public69.38%
3,393 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 5.19× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
- Reported zero revenue in 5 of the last 8 disclosed periods.
- 52-week range spans 5.19× (₹27.94 to ₹145) — an unusually wide band.
Peer comparison
Trading · ranked #74 of 674 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Enterprises Limited | ₹4,14,150 Cr | 160.88 | 4.37 | 3.93% | 6.78% |
| Avenue Supermarts Limited | ₹2,40,548 Cr | 78.65 | 9.83 | 12.14% | 4.29% |
| Trent Ltd. | ₹1,49,433 Cr | 81.73 | 21.41 | 24.62% | 8.64% |
| FSN E-Commerce Ventures Ltd. | ₹98,675 Cr | 370.43 | 68.37 | 13.87% | 2.41% |
| Vishal Mega Mart Limited | ₹47,649 Cr | 53.53 | 6.4 | 11.32% | 6.61% |
| Aegis Logistics Limited | ₹47,511 Cr | 37.97 | 7.84 | 14.83% | 13.95% |
| Aditya Infotech Limited | ₹45,256 Cr | 94.83 | 24.14 | 19.61% | 9.77% |
| Premier Energies Limited | ₹44,224 Cr | 26.56 | 10.27 | 35.05% | 19.67% |
| Redington Limited | ₹30,778 Cr | 17.11 | 3.03 | 14.67% | 1.33% |
| Honasa Consumer Limited | ₹15,361 Cr | 60.87 | 10.87 | 14.16% | 9.75% |
| Arvaya Healthcare Ltd.(this company) | ₹586 Cr | 813.33 | 9.88 | -2.06% | 3.59% |
AI analysis
AI-generated · google/gemini-2.5-flashArvaya Healthcare Ltd. (BIJOYHANSLTD) has a market capitalization of Rs 551 Cr. The company reported revenue of Rs 0.47 Cr and a profit margin of 0%. Its book value stands at Rs 12.08. The 52-week high for the share price was Rs 114.71, and the 52-week low was Rs 24.15.
Positives
- +The debt-to-equity ratio is low at 0.01.
- +Promoter holding remains consistent with no reported pledges.
Negatives
- −The company has reported negative return on equity (-206.4%) and return on capital employed (-1.9752%).
- −Current quarter revenue for Mar 2026 is reported as Rs 0 Cr, indicating no operational revenue.
- −The profit margin is 0%, indicating no profitability from operations.
- −The company is under ESM Stage 1 surveillance, which signifies increased regulatory scrutiny.
Financial performance
The company's revenue in Mar 2025 was Rs 0.4687403 Cr, following a revenue of Rs 0.5834072 Cr in Mar 2024. Net profit was Rs 0.1361204 Cr in Mar 2025, an improvement from a net loss of Rs -0.1172183 Cr in Mar 2024. Annual revenue experienced a decline from Rs 0.6147234 Cr in Mar 2021 to Rs 0.4687403 Cr in Mar 2025.
Profitability & returns
Arvaya Healthcare Ltd. currently reports a return on equity (ROE) of -206.4% and a return on capital employed (ROCE) of -1.9752%. The earnings per share (EPS) for the last reported period was Rs 0.45 in Mar 2025. The company's profit margin is 0% currently.
Balance sheet
The company's debt-to-equity ratio is 0.01, indicating low leverage. The book value per share is Rs 12.08. No dividend yield is reported.
Ownership & pledges
There are no reported promoter pledges. The number of shareholders is 3393.
Regulatory & surveillance
The company is currently under ESM (Enhanced Surveillance Measure) Stage 1, with measures including ESM. This indicates increased monitoring from regulatory bodies.
Data as of — price: 2026-09-12 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.